Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Chk1 inhibitor
DRUG CLASS:
Chk1 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
ACR-368 (25)
MK-8776 (3)
SRA737 (2)
LY 2603618 (2)
AZD-7762 (1)
CHIR-124 (1)
PD-407824 (1)
PF-00477736 (1)
CCT244747 (0)
ESP-01 (0)
PEP07 (0)
RG7741 (0)
ACR-368 (25)
MK-8776 (3)
SRA737 (2)
LY 2603618 (2)
AZD-7762 (1)
CHIR-124 (1)
PD-407824 (1)
PF-00477736 (1)
CCT244747 (0)
ESP-01 (0)
PEP07 (0)
RG7741 (0)
›
Associations
(36)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
ACR-368
Sensitive: B - Late Trials
ACR-368
Sensitive
:
B
ACR-368
Sensitive: B - Late Trials
ACR-368
Sensitive
:
B
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
ACR-368
Sensitive: B - Late Trials
ACR-368
Sensitive
:
B
ACR-368
Sensitive: B - Late Trials
ACR-368
Sensitive
:
B
BRCA1 mutation
Ovarian Serous Adenocarcinoma
BRCA1 mutation
Ovarian Serous Adenocarcinoma
olaparib + ACR-368
Sensitive: C2 – Inclusion Criteria
olaparib + ACR-368
Sensitive
:
C2
olaparib + ACR-368
Sensitive: C2 – Inclusion Criteria
olaparib + ACR-368
Sensitive
:
C2
BRCA2 mutation
Ovarian Serous Adenocarcinoma
BRCA2 mutation
Ovarian Serous Adenocarcinoma
ACR-368
Sensitive: C2 – Inclusion Criteria
ACR-368
Sensitive
:
C2
ACR-368
Sensitive: C2 – Inclusion Criteria
ACR-368
Sensitive
:
C2
BRCA1 mutation
Ovarian Serous Adenocarcinoma
BRCA1 mutation
Ovarian Serous Adenocarcinoma
ACR-368
Sensitive: C2 – Inclusion Criteria
ACR-368
Sensitive
:
C2
ACR-368
Sensitive: C2 – Inclusion Criteria
ACR-368
Sensitive
:
C2
CCNE1 amplification
Ovarian Cancer
CCNE1 amplification
Ovarian Cancer
ACR-368 + LY3300054
Sensitive: C3 – Early Trials
ACR-368 + LY3300054
Sensitive
:
C3
ACR-368 + LY3300054
Sensitive: C3 – Early Trials
ACR-368 + LY3300054
Sensitive
:
C3
PIK3CA mutation
Solid Tumor
PIK3CA mutation
Solid Tumor
ACR-368 + LY3023414
Sensitive: C3 – Early Trials
ACR-368 + LY3023414
Sensitive
:
C3
ACR-368 + LY3023414
Sensitive: C3 – Early Trials
ACR-368 + LY3023414
Sensitive
:
C3
SRSF2 mutation
Acute Myelogenous Leukemia
SRSF2 mutation
Acute Myelogenous Leukemia
ACR-368
Sensitive: C3 – Early Trials
ACR-368
Sensitive
:
C3
ACR-368
Sensitive: C3 – Early Trials
ACR-368
Sensitive
:
C3
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
olaparib + ACR-368
Sensitive: C3 – Early Trials
olaparib + ACR-368
Sensitive
:
C3
olaparib + ACR-368
Sensitive: C3 – Early Trials
olaparib + ACR-368
Sensitive
:
C3
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
olaparib + ACR-368
Sensitive: C3 – Early Trials
olaparib + ACR-368
Sensitive
:
C3
olaparib + ACR-368
Sensitive: C3 – Early Trials
olaparib + ACR-368
Sensitive
:
C3
BRCA wild-type
Triple Negative Breast Cancer
BRCA wild-type
Triple Negative Breast Cancer
ACR-368
Sensitive: C3 – Early Trials
ACR-368
Sensitive
:
C3
ACR-368
Sensitive: C3 – Early Trials
ACR-368
Sensitive
:
C3
BRCA1 3363delGAAA
Triple Negative Breast Cancer
BRCA1 3363delGAAA
Triple Negative Breast Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
BRCA1 5396insC
Triple Negative Breast Cancer
BRCA1 5396insC
Triple Negative Breast Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
BRCA2 5396insC
Triple Negative Breast Cancer
BRCA2 5396insC
Triple Negative Breast Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
CACNA1D E953D
Triple Negative Breast Cancer
CACNA1D E953D
Triple Negative Breast Cancer
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
TP53 R273H
Triple Negative Breast Cancer
TP53 R273H
Triple Negative Breast Cancer
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
PTEN V85
Triple Negative Breast Cancer
PTEN V85
Triple Negative Breast Cancer
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
BRCA2 deletion
Prostate Cancer
BRCA2 deletion
Prostate Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
BRCA2 mutation
Ovarian Serous Adenocarcinoma
BRCA2 mutation
Ovarian Serous Adenocarcinoma
ACR-368 + LY3023414
Sensitive: D – Preclinical
ACR-368 + LY3023414
Sensitive
:
D
ACR-368 + LY3023414
Sensitive: D – Preclinical
ACR-368 + LY3023414
Sensitive
:
D
BCL2L1 overexpression
Pancreatic Cancer
BCL2L1 overexpression
Pancreatic Cancer
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
CHEK1 overexpression
Pancreatic Cancer
CHEK1 overexpression
Pancreatic Cancer
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
CHEK1 overexpression + MYC overexpression
Small Cell Lung Cancer
CHEK1 overexpression + MYC overexpression
Small Cell Lung Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
MYC amplification
Small Cell Lung Cancer
MYC amplification
Small Cell Lung Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
BRCA1 mutation + TP53 mutation
Breast Cancer
BRCA1 mutation + TP53 mutation
Breast Cancer
AZD1775 + SRA737
Sensitive: D – Preclinical
AZD1775 + SRA737
Sensitive
:
D
AZD1775 + SRA737
Sensitive: D – Preclinical
AZD1775 + SRA737
Sensitive
:
D
TP53 mutation
Ovarian Cancer
TP53 mutation
Ovarian Cancer
AZD1775 + SRA737
Sensitive: D – Preclinical
AZD1775 + SRA737
Sensitive
:
D
AZD1775 + SRA737
Sensitive: D – Preclinical
AZD1775 + SRA737
Sensitive
:
D
MYCN amplification
Neuroblastoma
MYCN amplification
Neuroblastoma
olaparib + MK-8776
Sensitive: D – Preclinical
olaparib + MK-8776
Sensitive
:
D
olaparib + MK-8776
Sensitive: D – Preclinical
olaparib + MK-8776
Sensitive
:
D
MYCN amplification
Medulloblastoma
MYCN amplification
Medulloblastoma
olaparib + MK-8776
Sensitive: D – Preclinical
olaparib + MK-8776
Sensitive
:
D
olaparib + MK-8776
Sensitive: D – Preclinical
olaparib + MK-8776
Sensitive
:
D
TP53 mutation + KRAS mutation
Colon Cancer
TP53 mutation + KRAS mutation
Colon Cancer
LY 2603618
Sensitive: D – Preclinical
LY 2603618
Sensitive
:
D
LY 2603618
Sensitive: D – Preclinical
LY 2603618
Sensitive
:
D
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
MK-8776
Sensitive: D – Preclinical
MK-8776
Sensitive
:
D
MK-8776
Sensitive: D – Preclinical
MK-8776
Sensitive
:
D
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
LY 2603618
Sensitive: D – Preclinical
LY 2603618
Sensitive
:
D
LY 2603618
Sensitive: D – Preclinical
LY 2603618
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login